0000000000517427

AUTHOR

Antonio Vita

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

research product

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

research product